A study published by the Canadian Journal of Pain reports that patients with chronic pain who used medical marijuana experienced measurable improvements in pain-related outcomes, mental health indicators and overall quality of life over a 24-week period.
The prospective observational study was led by Dr. Hance Clarke, Director of Pain Services at University Health Network in Toronto, and was published this week in the Canadian Journal of Pain. The research evaluated patient-reported outcomes among individuals receiving medical marijuana under the supervision of a health-care provider as part of routine clinical practice across multiple Canadian provinces.
“While the term ‘medical cannabis’ is widely used, this study specifically evaluated outcomes among patients using medical cannabis under the supervision of a health-care provider,” said Dr. Clarke, Principal Investigator and Clinician at UHN. “Among chronic pain patients who remained on an authorized medical cannabis product at six months, improvements were observed in pain severity, pain interference, and several health-related outcomes. These findings support the potential role of medical cannabis in selected patients as indicated by preliminary real-world data, while highlighting the importance of clinician involvement in monitoring efficacy, safety, and ongoing patient outcomes.”
Researchers used validated assessment tools commonly employed in pain and mental health research to measure changes from baseline. The results showed statistically significant improvements in pain interference, pain intensity, anxiety, depressive symptoms and quality of life. However, the magnitude of change did not reach established minimal clinically important difference thresholds, a finding the authors note highlights the need for further placebo-controlled randomized trials to determine optimal dosing, formulations and methods of administration.
The study was conducted through the MyMedi.ca platform, which supports physician-supervised medical marijuana access and patient monitoring. Participants were enrolled from seven provinces, and researchers continue to recruit additional patients as the study remains ongoing.
Karolina Urban, Executive Vice President of Scientific and Medical Affairs at Avicanna, said the publication represents a milestone for real-world marijuana research. “High-quality, prospective real-world data can play a critical role in complementing randomized clinical trials, informing clinical practice, and supporting the responsible integration of cannabinoid-based medicines into evidence-based care,” she said.
In addition to evaluating pain and mental health measures, the ongoing research is designed to assess changes in sleep patterns, epilepsy symptoms and the use of other medications over time, offering a broader look at how medical marijuana may fit into long-term patient care under clinical supervision.
More articles from The Marijuana Herald:
